Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Take the Money and Run -- Ignore unavailable to you. Want to Upgrade?

To: MulhollandDrive who wrote (4010)	6/19/2002 11:30:34 AM
From: Original Mad Dog	Read Replies (1) \| Respond to of 17639

You would think after all the unkind things he said about MER, Morgan Stanley would be a little nicer to him. <g>

To: MulhollandDrive who wrote (4010)	6/19/2002 11:38:10 AM
From: Jorj X Mckie	Read Replies (1) \| Respond to of 17639

or take the opposite position from what I say. SCIO just broke the R at 31.00. I'll be looking for the exit point now....assuming we get a little one, I am done with this POS. $51M in sales $1.4B Market cap here is their summary from yahoo Financial Summary Scios discovers, develops, manufactures and commercializes novel human therapeutics based upon its capabilities in both protein-based and small-molecule drug discovery and development. For the three months ended 3/31/02, revenues increased 38% to $16.4 million. Net loss totaled $25.2 million, up from $4.2 million. Revenues reflect a one-time sale of bulk FGF to Kaken. Net loss reflects increased clinical and R&D costs related to Natrecor and kinase inhibitor programs.